SOM0226, a reprofiled drug for the treatment of TTR amyloidosis, has been presented at the XIIIth International Symposium on Amyloidosis in Groningen, The Netherlands. The product has been recognized as one of the most promising in-coming therapies by the scientific expert community in the field.